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Abstract
Background: The VP2 outer capsid protein Bluetongue Virus (BTV) is responsible for receptor
binding, haemagglutination and eliciting host-specific immunity. However, the assembly of this outer
capsid protein on the transcriptionally active viral core would block transcription of the virus. Thus
assembly of the outer capsid on the core particle must be a tightly controlled process during virus
maturation. Earlier studies have detected mature virus particles associated with intermediate
filaments in virus infected cells but the viral determinant for this association and the effect of
disrupting intermediate filaments on virus assembly and release are unknown.
Results: In this study it is demonstrated that BTV VP2 associates with vimentin in both virus
infected cells and in the absence of other viral proteins. Further, the determinants of vimentin
localisation are mapped to the N-terminus of the protein and deletions of aminio acids between
residues 65 and 114 are shown to disrupt VP2-vimentin association. Site directed mutation also
reveals that amino acid residues Gly 70 and Val 72 are important in the VP2-vimentin association.
Mutation of these amino acids resulted in a soluble VP2 capable of forming trimeric structures
similar to unmodified protein that no longer associated with vimentin. Furthermore,
pharmacological disruption of intermediate filaments, either directly or indirectly through the
disruption of the microtubule network, inhibited virus release from BTV infected cells.
Conclusion: The principal findings of the research are that the association of mature BTV particles
with intermediate filaments are driven by the interaction of VP2 with vimentin and that this
interaction contributes to virus egress. Furthermore, i) the N-terminal 118 amino acids of VP2 are
sufficient to confer vimentin interaction. ii) Deletion of amino acids 65–114 or mutation of amino
acids 70–72 to DVD abrogates vimentin association. iii) Finally, disruption of vimentin structures
results in an increase in cell associated BTV and a reduction in the amount of released virus from
infected cells.
Background
Bluetongue virus (BTV), an insect (Culicoides sp) transmit-
ted double-layered non-enveloped virus, is the type spe-
cies virus of the genus Orbivirus, in the family Reoviridae.
BTV is an economically important virus and causes hem-
orrhagic disease in sheep and other ruminants [1]. The
virus has a genome consisting of ten double stranded (ds)
RNA segments, located in a core particle made up of two
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major proteins (VP3 and VP7) and three minor proteins
(VP1, VP4 and VP6). In the mature particle, this core is
coated by two outer capsid proteins, VP2 (110 kDa) and
VP5 (60 kDa) (see schematic, Fig. 1). The most exposed
protein on the mature virion, VP2, is responsible for
receptor binding [2-4], haemagglutinating activity [5] and
elicits host specific immunity [6-8]. The smaller protein,
VP5, is involved in cell penetration during the initial
stages of infection [9,10]. After entry into cells, the virus is
uncoated by removal of VP2 and VP5 to yield the core par-
ticle that is transcriptionally active. This complex is an
end-point in virus disassembly and protects the viral
dsRNA genome from intracellular surveillance mecha-
nisms.
Like other members of Reoviridae, BTV replicates in the
cytoplasm of infected cells. Electron microscopic analysis
of thin sections of BTV infected cells have revealed a large
numbers of virus-specific tubules, and juxtanuclear inclu-
sions bodies containing virus-like particles in addition to
small numbers of intracellular virus particles (15). While
the tubules are multimers of NS1 [11], inclusion bodies
are predominantly formed by NS2 [12,13]. Similar to
rotavirus inclusion bodies [14], it has been speculated
that during BTV replication and assembly NS2 binds core
proteins, viral single-stranded (ssRNA) [15,16] and
recruits these components to the inclusion bodies [17].
Additionally, it has been hypothesised that the viral
genome interacts with the minor structural proteins to
form the transcriptase complex which is subsequently
encapsulated by a single shell of VP3 to form the subcore
of the assembling virus [18]. The subcore acts as a scaffold
for the deposition of VP7 trimers, thus forming a stable
core structure [19-21]. However, the outer capsid pro-
teins, VP2 and VP5 have not been localised to the viral
inclusion bodies and it is still not clear when and where
in the cell are they assembled on to the core. As the outer
capsid proteins, particularly VP2, would effectively block
the channels in the core that are used during transcription
of the viral genome it is unlikely that the coating of cores
would be an uncontrolled process.
Previous electron microscopy studies have indicated that
BTV particles can be found attached to vimentin interme-
diate filaments [22]. Negative staining of intact, infected
cells labelled with anti-VP2 antibody revealed that BTV
particles were also present under the cell membrane as
well as on the cell surface [23]. In addition, both virus
aggregates and single virion particles retain an association
with the cortical layer of the cytoskeleton following cell
lysis. This has lead to speculation that there may be inter-
action of the particle with the actin-rich cortical layer
underlying the cell membrane [23]. Recent studies have
shown that NS3, the only virus-coded glycoprotein of
BTV, interacts with VP2 as well as Tsg101 and the p11 sub-
unit of the heterotetrameric calpactin II complex, thereby
facilitating virus release [24,25]. Thus, in addition to its
role in virus attachment, VP2 is emerging as a key player
in the control of BTV assembly and egress from infected
cells. A detailed understanding of the control of VP2 asso-
ciation with the newly assembled core is therefore an
important step in understanding virus assembly and
egress.
In this manuscript we demonstrate that normal subcellu-
lar distribution of VP2 relies on an association with
vimentin intermediate filaments, and identify key resi-
dues in this interaction located in the N-terminus of the
protein. Furthermore, disruption of the vimentin filament
network using pharmacological inhibitors lead to a dis-
ruption of virus egress.
Results
In infected cells VP2 localises to punctuate areas within the 
cytoplasm
In order to assess the intracellular localisation of VP2 in
virus infection, cells were first infected with BTV-10 and
then VP2 detected by immunofluorescence microscopy.
At 4 hours post infection VP2 was found to be restricted to
punctuate areas within the cytoplasm (Fig. 2A). A similar
distribution of VP2 was observed when cells were trans-
fected with plasmids encoding VP2 or a VP2-GFP fusion
protein where the GFP was located at the C-terminus of
VP2 (Fig. 2B and 2C, respectively). However, fusion of
GFP to the N-terminus of VP2 altered the subcellular
localisation of the protein and resulted in a more diffuse
pattern of fluorescence (Fig. 2D). Western blot analysis of
Schematic of the mature BTV particle Figure 1
Schematic of the mature BTV particle. Organisation of 
the major structural proteins VP2, VP5, VP3 and VP7 in the 
architecturally complex BTV particle. On entry into cells the 
outer capsid proteins VP2 and VP5 are lost, releasing a tran-
scriptionally active core particle.
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the VP2 GFP fusion proteins confirmed that they were
expressed in cells as full-length proteins (Fig. 2F).
The N-terminus of VP2 is sufficient to direct sub-cellular 
localisation
Since the fusion of GFP to the N-terminus but not the C-
teriminus of VP2 altered its sub-cellular localisation we
hypothesised that the N-terminus of the protein con-
tained a signal necessary for intracellular localisation that
was disrupted in the fusion protein. To test this possibil-
ity, we expressed an N-terminal fragment of VP2 consist-
ing of the first 118 residues of the protein fused at its C-
terminus to GFP (Fig. 3A, VP21–118GFP). The distribution
of this deletion mutant was indistinguishable from that of
the full-length VP2-GFP protein (Fig. 3A, VP2 GFP), sug-
gesting that it contained the signals necessary for the sub-
cellular localisation of VP2. The punctuate pattern of
VP21–118GFP accumulation was distinct from what would
be expected if the chimeric protein had been incorporated
into aggresomes as there was no evidence of co-localisa-
tion with ubiquitin (Fig. 3A, ubiquitin).
VP2 in virus infected cells and VP21–118GFP associate with 
vimentin
Earlier electron microscopic studies of BTV infected cells
have suggested that the virus associates with the cell mem-
brane and with vimentin intermediate filaments [22,26].
In order to test where VP21–118GFP was localised within
cells, subcellular fractionation studies were carried out in
the presence of detergents at both 4°C and 37°C (Fig. 3B).
These studies were designed to separate soluble cytoplas-
mic proteins and lipid raft associated proteins from
cytoskeletal and nuclear fractions of the cell. As expected,
actin was present as both soluble and cytoskeletal associ-
ated insoluble forms under the conditions of the study.
Tubulin and untagged GFP were present predominantly
in the detergent soluble cytosolic fraction. The nuclear
membrane protein lamin was present predominantly in
the detergent insoluble fractions at both 4°C and 37°C,
although at the higher temperature the proportion of sol-
ubulised lamin was increased. Vimentin and VP2 co-seg-
regated in these fractionation studies, and were present
only in the detergent insoluble fractions (Fig. 3B). Thus,
fractionation studies supported association with VP2 with
detergent insoluble cell fractions containing vimentin.
Immunofluorescence was performed with each of the pro-
teins in the cell fractionation studies in Vero cells express-
ing VP21–118GFP. While there was no evidence that either
actin, tubulin or lamin co-localised with the VP2 deletion
mutant, all of the VP21–118GFP was detected in areas of the
cell rich in vimentin (Fig. 3C). Thus, in both cell fraction-
ation and colocalisation studies VP21–118GFP and vimen-
tin were detected together.
In order to confirm the association between vimentin and
full-length VP2, the distribution of vimentin and VP2 in
virus infected cells was monitored by immunoflorescence.
BTV infection of mammalian cells in tissue culture leads
to rapid changes in cell morphology with apoptosis,
which is triggered during virus entry [27]. Thus the distri-
bution of VP2 and vimentin was assessed at early (8
hours) and late (24 hours) timepoints following virus
infection (Fig. 3D). At 8 hours post infection vimentin
was distributed throughout the cell but was also present in
concentrated foci within the cytoplasm. At the same time-
point, VP2 was detected in concentrated foci within the
cells. Intriguingly, the largest foci of VP2 co-localised with
the largest foci of vimentin. All the VP2 in detected in
Distribution of VP2 within infected and transfected Vero  cells by fluorescence microscopy Figure 2
Distribution of VP2 within infected and transfected 
Vero cells by fluorescence microscopy. A) Cells 
infected with BTV-10, B-E) transfected cells expressing B) 
VP2, C) VP2-GFP, D) GFP-VP2 and E) GFP only. VP2 in A 
and B were detected with anti VP2 monoclonal antibody 
(rabbit) and either FITC (A) or TRITC (B) conjugated sec-
ondary antibody. C-E were visualised based on GFP fluores-
cence. Expression of full-length, tagged VP2 variants was 
confirmed by western blot using an anti-GFP antibody (F).
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VP2 segregates with vimentin in infected and transfected cells Figure 3
VP2 segregates with vimentin in infected and transfected cells. A) Distribution of VP21–118GFP (left), VP2-GFP (cen-
tre), and VP2-GFP with ubiquitin (red, right) in transfected cells. Amino acids 1–118 give similar localisation to full-length pro-
tein. There is no evidence of co-localisation of ubuquitin with the punctuate distribution of VP2. B) Fractionation of untreated 
cells and cells transfected with plasmid expressing GFP or VP21–118GFP. Cells were solubulised in the presence of 1% Triton X-
100 and fractionated into detergent insoluble (DI) and detergent soluble (DS) fractions. Western blot was used to detect frac-
tionation of the cytoskeletal marker proteins actin, tubulin and vimentin and the nuclear envelope marker lamin A. Fractiona-
tion of VP21–118GFP and GFP was followed using anti-GFP antibody. VP21–118GFP co-fractionated with vimentin but none of the 
other proteins. C) Imunofluorescence microscopy co-localisation of VP21–118GFP with vimentin, lamin, actin and tubulin, as 
indicated. D) Distribution of vimentin (red) and untagged VP2 (green) in virus infected cells at 8 hours (top row) and 24 hours 
(bottom row) post infection. Note co-localisation of VP2 and vimentin even at early times post infection.
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virus infected cells was found associated with vimentin,
although not all the vimentin at this timepoint was asso-
ciated with VP2 (Fig. 3D). In contrast, at 24 hours post
infection, by which time there are substantial virus-
induced changes in cell morphology almost all the vimen-
tin and VP2 present in the cell colocalised (Fig. 3D). Thus,
data from virus infected cells confirm the VP2-vimentin
association detected with the VP21–118GFP deletion
mutant.
Deletion of amino acids 65–114 abolishes subcellular 
localisation of VP21–118GFP
Having established that VP21–118GFP and full-length VP2
both colocalised with vimentin we went on to perform
deletion mutagenesis of the VP21–118GFP mutant in order
to determine the regions of the protein critical to this
interaction. Five deletions were introduced to the 1–118
region of VP2, to produce in-frame truncations of this
region of the protein (Fig. 4A). Of these, deletion of the 49
amino acids between position 65 and 114 resulted in a
diffuse distribution of the truncated protein (Fig. 4B). Fur-
ther truncation of the protein, by introducing deletions
from amino acids 65–92 or 93–114 gave no further reso-
lution to the analysis, as both of these deletions abolished
punctuate localisation of the VP2 protein (Fig. 4B). Dele-
tions between amino acids 13 and 64 had no effect on the
localisation of the VP21–118GFP protein, suggesting that
this region does not contribute to the subcellular localisa-
tion of the protein.
Mutation of amino acids 70–72 of VP2 affects subcellular 
localisation but not multimerisation
The most likely reasons that deletions from 65–92 and
93–114 both resulted in diffuse localisation of the VP2
truncation mutant were that there were either multiple
localisation signals, or the signal extended across the
amino acid 92–93 junction, or these deletions had long-
distance effects on folding of the remaining VP2
sequences. In order to resolve these possibilities we car-
ried out site directed mutagenesis of conserved amino
acids in this region of the protein. Sequence alignment of
the sequence of the VP2 protein from 13 different BTV
serotypes revealed that there were four amino acid regions
within this sequence which were either completely con-
served or very similar. These were the regions G70 to L81,
D86 to K88, F98 to T100 and W104 to I109 (Fig. 5A). Five
sets of mutations were generated; the first four were
designed to mutate charged or conserved amino acids in
each of the four conserved regions to alanine. The ration-
ale for selecting the charged amino acids for mutation was
that it was expected that these proteins would be more
likely to be solvent exposed and thus available to interact
with vimentin. The fifth mutation was to target the con-
served GXV motif present at position 70–72. Since muta-
tion of these amino acids to alanine would have been a
very conservative change, and these residues are part of
the only strongly hydrophobic region of the truncated
protein, GVV was mutated to DVD. This mutation has the
effect of altering the mean hydrophobicity of this region
Deletion anlysis of VP21–118GFP Figure 4
Deletion anlysis of VP21–118GFP. A) Schematic showing the position of deletions generated in the VP21–118GFP. B) Fluores-
cence images showing the distribution of VP21–118GFP deletion mutants from A. Deletion of 65–92 and 93–114 was sufficient 
to abolish intracellular localisation of the N terminus of VP2.
B A
VP21-118GFP
32   65 ΔVP233-64GFP
ΔVP293-114GFP
64   93
92   115
ΔVP265-92GFP
118 1
12          65 ΔVP213-64GFP
ΔVP265-114GFP 64      115
ΔVP233-64GFP    ΔVP265-92GFP      ΔVP293-114GFP
VP21-118 GFP       ΔVP213-64GFP      ΔVP265-114GFPVirology Journal 2007, 4:7 http://www.virologyj.com/content/4/1/7
Page 6 of 12
(page number not for citation purposes)
of the truncated VP2, such that the hydrophobic patch
normally present in this region of protein has mean
hydrophilic properties (Fig. 5B).
On expression, all of the four alanine mutations had sim-
ilar punctate accumulation patterns to the unmodified
VP2 sequence (Fig. 5C). In contrast, the mutation of the
GVV to DVD at positions 70–72 resulted in a diffuse pat-
tern of expression similar to that seen with the ΔVP265–
92GFP and ΔVP293–114GFP deletion mutants. Vimentin
targeted immunofluorescence with cells expressing the
DVD (M5) mutant revealed that the association between
vimentin and VP2 had been broken (Fig. 5D). Because the
M5 mutation was designed to alter the hydrophobicity
profile of the vimentin binding region of VP2 it was pos-
sible that the changes in accumulation seen were a result
of global changes in the folding of the VP2 protein. In
order to address this possibility, the M5 mutation was
introduced into the full-length VP2 protein, and this pro-
tein expressed in insect cells using the baculovirus expres-
sion system. Unmodified VP2 multimerises to form a
trimeric triskelion structure present on the outer surface of
the mature virus particle [28]. By separating purified,
unmodified VP2 under native conditions it is possible to
detect monomeric, dimeric and trimeric forms of the pro-
tein (Fig. 5E). Separation of the full-length M5 VP2
mutant under the same conditions resulted in the forma-
tion of a similar proportion of each of the multimeric
states of the VP2 protein as the unmodified protein. Thus
the mutation that prevented the association of VP2 with
vimentin did not prevent the formation of higher order
multimers of the VP2 protein. This suggests that while it is
possible that the local protein architecture was affected by
the M5 mutation the overall folding of the protein was
similar enough to the unmodified protein that multimer-
isation was unaffected.
Pharmacological disruption of vimentin intermediate 
filaments inhibits virus release
The vimentin intermediate filament network has a radial
organisation, extending outwards from the cell centre.
This localization partially overlaps with that of microtu-
bules there is evidence that the two filament systems inter-
act [29,30]. Indeed, vimentin structures move along
microtubules [29,31-33]. Therefore, if the vimentin-VP2
interaction was important for BTV assembly and/or egress
we predicted that pharmacological disruption of either
microtubules or vimentin would result in changes of the
amount of virus produced or the amount of virus released
from infected cells. To test this possibility we carried out
pharmacological experiments with colchicine and acryla-
mide which specifically disrupt the microtubule and
vimentin intermediate filament networks respectively.
Consistent with our previous experiments, in untreated
cells vimentin was detected throughout the cytoplasm and
this distribution was unaffected by the expression of full-
length, untagged VP2. However, in the presence of colch-
icine, as expected, there was a redistribution of vimentin
and VP2 towards the nucleus (Fig. 6A). This observation
supports other observations that vimentin intermediate
filaments are organised by the microtubule network
[29,30]. The redistribution of vimentin was even more
dramatic on the addition of acrylamide which resulted in
a collapse of the intermediate filament network and a
change in cell morphology to a more rounded shape (Fig.
6A). To test the effect of these changes in vimentin distri-
bution on virus replication and release, virus was
adsorbed to cells and then cells were treated with either
colchicine (Fig. 6B) or acrylamide (Fig. 6B). Indirect dis-
ruption of vimentin with colchicine resulted in 2.5 times
more cell associated virus and a five-fold reduction in the
amount of the released virus detected compared to
untreated control cells. Addition of acrylamide resulted in
a 50 fold reduction in the amount of released virus and a
250 fold increase in the amount of cell associated virus at
24 hours post infection. These data suggest that disrup-
tion of vimentin either directly or indirectly inhibits the
trafficking of mature virus particles out of virus infected
cells.
Discussion
The specific roles of the two proteins in the orbivirus outer
capsid in the processes of virus attachment and mem-
brane penetration have now been elucidated [4,9,10].
Intriguingly, one of these proteins, VP2, also plays a role
in virus egress from infected cells as it binds a viral non-
structural protein that acts as a molecular bridge between
the virus particle and cellular export and release factors
[24,25,34]. Thus, VP2 is important to both the infectivity
and egress of BTV particles. The proteins that are required
to form the transcriptionally active orbivirus core struc-
ture have all been localised to inclusion bodies within
virus infected cells [17,35,36]. However, the outer capsid
proteins do not localise to inclusions and therefore the
site of assembly of mature virus particles before transport
out of infected cells is unknown. Members of other genera
in the Reoviridae cannot be used as a model for BTV in
outer capsid assembly, as this information is either not
available, or the outer capsid and assembly process is
quite distinct. For example, unlike BTV, significant steps
in the outer capsid assembly of rotavirus are sequestered
in the endoplasmic reticulum [37]. Thus, in order to gain
further insight into the assembly and intracellular traffick-
ing of BTV, the localisation of VP2 in virus infected cells
was followed using immunofluorescence microscopy. In
virus infected cells VP2 was located in punctuate distribu-
tion throughout the cytoplasm even at quite early times
post infection (Fig. 2). This distribution could be mim-
icked in cells transfected with plasmid expressing VP2 pro-
tein, full-length VP2 fused at its C-terminus to GFP, or theVirology Journal 2007, 4:7 http://www.virologyj.com/content/4/1/7
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Fine mapping of the influence of VP2 amino acids 65–114 on localisation Figure 5
Fine mapping of the influence of VP2 amino acids 65–114 on localisation. A) Schematic showing the alignment of 
BTV-10 VP2 protein sequence to a consensus sequence generated from alignment of 13 BTV serotypes. Mutants generated 
(M1-M5) which disrupt conserved amino acid positions are indicated. Amino acids which are completely conserved or con-
served in charge are indicated by (*) or (:) respectively. Weakly conserved amino acids are indicated by (.). Amino acids tar-
geted for mutagenesis are shown in bold in the consensus and BTV-10 VP2 sequences. Sequences predicted in silico to form β-
sheet are underlined. B) Kyte and Dolittle mean hydrophobicity profile[45], generated using a scan window size of 13 on BTV-
10 VP2 1–114 and M5 VP2 1–114, as indicated. C) Fluorescence microscopy images of cells transfected with plasmid expressing 
VP21–118GFP or M1-M5 as indicated. Intracellular localisation of VP2 is abolished in M5. D) Co-localisation of VP21–118GFP and 
M5 with vimentin (red). Vimentin distribution is unaffected in cells expressing M5 but the VP2 mutant is found throughout the 
cell. E) Trimerisation of full-length VP2 carrying the M5 mutation. Western blot of non-denatured samples for unmodified (left 
panel) and M5 (right panel) VP2 variants. Note that trimerisation is unaffected in the M5 mutant.
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Disrupting vimentin inhibits virus release in BTV infected cells Figure 6
Disrupting vimentin inhibits virus release in BTV infected cells. A) Co-localization of untagged VP2 with vimentin in 
transfected cells. Top, untreated cells; Middle, cells treated with colchicine to disrupt microtubules; bottom, cells treated with 
acrylamide to disrupt vimentin. In each row VP2 and vimentin localisation are shown in green and red respectively. As 
expected, disruption of microtubules with colchicine causes a rearrangement in the localisation of vimentin. B) Effect of treat-
ing cells with colchicine on the release of virus from infected cells. Cells and culture medium were harvested at 4, 8 and 24 
hours post infection with BTV-10 in untreated and colchicine (5 μg/ml) treated cells. Control samples are labelled 4c, 8c and 
24c, respectively. The titre of cell associated and released virus for each timepoint normalised to 100% for untreated cells. Col-
chicine treatment resulted in a time dependent increase in the titre of cell associated virus and a time-dependent decrease in 
the titre of virus in the culture medium. D) As C but for cells treated with acrylamide (50 μM) to directly disrupt the vimentin 
network. Effect of acrylamide was similar but much faster and more dramatic than that observed by indirect disruption of 
vimentin through disruption of microtubules using colchicine. For C and D error bars indicate the standard error of three rep-
licates of the experiments.
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N-terminal 118 amino acids of VP2 fused to GFP (Fig. 2;
Fig. 3). Furthermore, it was found that VP2 co-fraction-
ated with the intermediate filament protein vimentin in
fractionation studies, and co-localised with vimentin in
immunofluorescence of VP2 in transfected and virus
infected cells (Fig. 3). These data are consistent with ear-
lier electron microscopy studies that have found mature
virus particles in linear arrays along intermediate fila-
ments in infected cells [26]. Furthermore they demon-
strate for the first time that the determinant for BTV-
vimentin association is the VP2 protein.
The vimentin associated localisation of VP2 in virus
infected and VP2 transfected cells was quite distinct from
the aggresome structure that has been noted following the
overexpression of certain proteins. There was no evidence
of the cage-like vimentin arrangement around VP2 which
is observed with aggresomes [38,39]. Nor was there any
evidence that ubiquitin co-localised with VP2 in trans-
fected cells (Fig. 3).
Using a deletion mutagenesis strategy we were able to
localise the vimentin localisation signal within VP2 to the
region encompassing the amino acids 65–114 (Fig. 4).
This was confirmed by systematic site-directed mutagene-
sis of conserved amino acids within this region to identify
key residues in VP2-vimentin association. Of five sets of
mutants, which changed a total of 13 conserved amino
acids, only one, mutation of GVV to DVD at postions 70–
72, prevented co-localisation of VP2 with vimentin (Fig.
5). This mutant was specifically designed to alter the
hydrophobicity profile of the VP2 region from amino
acids 63–80 to make it more hydrophilic. Thus, it was ini-
tially unclear whether the disruption of the association
between VP2 and vimentin was due to global changes in
the folding of the protein. However, when the DVD muta-
tion was introduced into full-length VP2 the ability of the
recombinant protein to assemble into trimeric VP2 struc-
tures was equivalent to that of unmodified protein. Thus,
if there are changes to the structure of the protein induced
by the DVD mutation, they occur at a local as opposed to
a global level within the protein. These data indicate the
DVD mutation either disrupts vimentin-VP2 association
because the conserved GXV motif at position 70–72 is
necessary for vimentin interaction or, like the deletions of
aminio acids 65–92 or 93–114, mutation of this motif
results in local rearrangement of the structure of VP2. At a
primary sequence level, there is no apparent homology
between this region of VP2 and vimentin, or any other
known vimentin interacting protein. Therefore, in combi-
nation with the identity of the completely conserved
amino acid (Glycine) and our mutagenesis data it is likely
that VP2-vimentin interaction involving amino acids 65–
114 is conformationally dependent.
Within the cell vimentin is emerging as a key player in
intracellular trafficking. Vimentin structures have been
shown to move along microtubules, and two candidate
motors had been identified for this motility: conventional
kinesin, and more recently, cytoplasmic dynein [29,31-
33]. Significantly for VP2-vimentin interactions, the
motility of vimentin intermediate filaments is principally
from the nucleus towards the cell surface in BHK-21 cells
[33]. Indeed, in this study when vimentin intermediate fil-
aments were disrupted pharmacologically either directly,
or indirectly by disrupting microtubules, there was a dra-
matic reduction in the amount of virus released from
infected cells (Fig. 6). This reduction in release was not
entirely due to a decrease in overall virus synthesis as, par-
ticularly in the case of acrylamide treatment, decrease in
BTV release corresponded to an increase in cell associated
virus (Fig. 6B). A plausible explanation for these observa-
tions would be that VP2-vimentin interaction is involved
in the transport of mature virus particles. This hypothesis
would correlate well with recent evidence that the viral
non-strucutral protein NS3, which interacts with VP2 at its
C-terminus [24], interacts at its N-terminus with the cellu-
lar release factor Tsg101 [25]. In this model, mature virus
particles would be assembled from cores released from
juxtanuclear inclusions, trafficked to the cell surface
through vimentin association and released through the
interaction of NS3 and Tsg101. Future work will focus on
testing the validity of this model.
Conclusion
Principal conclusions from this study are: i)The interac-
tion that has been observed between mature BTV particles
and vimentin intermediate filaments [26] is dependent
on outer capsid protein VP2. ii) Amino acids 1–118 of
VP2 are sufficient to determine vimentin association and
within this region deletion of residues 65–114 or muta-
tion of amino acids 70–72 to DVD is sufficient to abolish
vimentin interaction. iii) Disruption of the vimentin
intermediate filament network leads to an accumulation
of intracellular virus particles and a reduction in virus
release possibly because vimentin is involved in BTV traf-
ficking to the cell surface.
Methods
Cells and viruses
A cell culture-adapted BTV serotype 10isolate (BTV-10;
Colorado isolate) was used. The virus was propagated in
Vero (African Green Monkey Kidney) cells and its titre was
determined by plaque assay in BSR (Baby Hamster Kid-
ney) cells. Vero and BSR cells were were incubated at 37°C
in Dulbecco's modified Eagle's medium (Gibco BRL) con-
taining 10% foetal calf serum (FCS), 100U penicillin/ml,
and 100 μg streptomycin/ml (Sigma-Aldrich Chemical
Co., St. Louis, Mo.). Recombinant baculovirus expressing
bluetongue virus VP2 (AcMNPV-VP2) was propagated inVirology Journal 2007, 4:7 http://www.virologyj.com/content/4/1/7
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Spodoptera frugiperda (Sf21) cells grown in suspension cul-
tures at 28°C in TC100 medium (Sigma-Aldrich) supple-
mented with 10% foetal calf serum. Purification of
recombinant VP2 was completed as described [4,40].
Antibodies and pharmacological reagents
Monoclonal antibody against BTV-10 VP2 was a gift from
N J. MacLachlan (School of Vet. Med., Davis, CA). Poly-
clonal antibodies against vimentin (goat), actin (goat)
and GFP (rabbit) were purchased from Santa Cruz Bio-
tech, CA. Polyclonal antibodies against ubiquitinin, tubu-
lin and nuclear lamin were purchased from Abcam
(Cambridge UK). Tetramethyl rhodamine isothiocyanate
(TRITC) and fluorescein isothiocyanate (FITC)-conju-
gated secondary antibodies were purchased from Sigma-
Aldrich. For pharmacological experiments, molecular
grade acrylamide and cholchicine were purchased from
Sigma-Aldrich.
Construction of fusion proteins and VP2 mutants
Plasmids expressing VP2 were constructed by PCR ampli-
fying the full-length L2 gene from BTV-10 and ligating it
downstream of the Pol II or T7 RNA polymerase promot-
ers in the pCAG-GS (The CABRI Consortium) or pCITE-2a
vectors (Novagen), respectively.
To express the N-terminal GFP tagged VP2 fusion protein
(GFP-VP2), GFP was amplified by PCR without its stop
codon and inserted in-frame upstream of the VP2 protein.
To express C-terminal GFP tagged VP2 (VP2-GFP) the nor-
mal VP2 stop codon was mutated to a restriction site using
the QuickChange™ mutagenesis system (Stratagene, La
Jolla, CA) and the GFP gene was excised from the pEGFP
plasmid and ligated in-frame to the modified VP2 gene.
VP21–118GFP was produced by cloning EGFP as a blunt-
end fragment from pEGFP (Clontech, Mountain View,
CA) into a plasmid containing the full-length BTV-10 VP2
gene cut with AflII. For deletion analyses, site-directed
mutagenesis was used to introduce unique restriction sites
in VP21–118GFP plasmid and internal deletions were intro-
duced by cutting at the inserted restriction sites and reli-
gating the plasmid. Mutations were designed to introduce
minimal changes to the amino acid sequence of the result-
ing deletion mutants. The QuickChange™ system (Strata-
gene) was used to generate amino acid substitution
mutants in the VP21–118GFP plasmid according to the
manufacturer's protocol.
To express full-length VP2 with the DVD mutation at
amino acids 70–72 the transfer vector pAcYM10.2 [40]
expressing wild-type VP2 was mutated using the same
primers and protocol as to introduce the mutation into
the VP21–118GFP plasmid. The orientation of constructs in
all the plasmids was examined by restriction enzyme anal-
ysis, and the authenticity of each construct was confirmed
by DNA sequencing using the ABI Prism® Big Dye™Termi-
nator cycle sequencing ready reaction kits (Applied Bio-
systems, Foster City, CA).
Isolation of recombinant baculoviruses expressing mutant 
VP2 protein
Recombinant baculovirus expressing the DVD mutant for
VP2 was produced using standard baculovirus recombina-
tion procedures as described [41]. Recombinant baculovi-
ruses were plaque purified and propagated in Sf21 cells as
described elsewhere [41].
Expression of proteins from transfected plasmids and virus 
infection
Vero cells were plated in six well plates and plasmid DNA
was transfected with Lipofectamine Plus™ transfection
reagent (Invitrogen, Carlsbad, CA) following the manu-
facturer's instructions. Expression was analysed at 12–72
hours post-transfection as indicated in the text.
Confocal microscopy
BTV infected or plasmid transfected cells were fixed on
coverslips by incubation for 30 min at room temperature
with 4% (w/v) paraformaldehyde in phosphate-buffered
saline (PBS). Cover slips were then incubated for 15 min
at room temperature with 1% Triton X in PBS (pH 7.5)
and blocked for an hour with PBS containing 1% bovine
serum albumin. Cells were incubated with primary anti-
bodies diluted (1:100) in blocking buffer for 1 h, washed
5 times with PBS then incubated with appropriate second-
ary antibodies conjugated to TRITC (1:64) or FITC
(1:128) prior to washing with PBS and mounting in
Vectashield mounting media (Vector Laboratories, Burl-
ingham, CA). Coverslips were examined with a Zeiss Axio-
vert 200 M laser-scanning microscope fitted with a
helium-argon laser. Images were acquired and analysed
using LSM 510 confocal software (Zeiss). For GFP imag-
ing, cells grown on cover slips were transfected with the
different GFP chimeras, washed and fixed at 12 hour inter-
vals, from 0 to 48 hours post transfection as described pre-
viously.
Isolation of Detergent Soluble (DS) and Insoluble (DI) 
fractions
Fractions were essentially prepared as described [42], with
some minor modifications. In brief, 72 hours post trans-
fection, cells were rinsed twice with ice-cold PBS, re-sus-
pended and centrifuged at 1000 g for 5 minutes (Sanyo
Micro Centaur, Jepson Bolton & Co Ltd, Watford, UK).
The cell pellet was lysed for 30 min at 4°C in 0.2 ml of a
25 mM Tris-HCl (pH 7.5) buffer, containing 150 mM
NaCl, 5 mM EDTA, and 1% Triton X-100, followed by 30
strokes in a dounce homogeniser. detergent soluble and
insoluble fractions were separated by centrifugation for 15
minutes at 12,000 g (4°C) and resolved by SDS/10%Virology Journal 2007, 4:7 http://www.virologyj.com/content/4/1/7
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Polyacrylamide gel electrophoresis (PAGE) [43]. In some
experiments, cell lysis was carried out at 37°C instead of
4°C, and 1% Nonidet P-40 (NP40) was used instead of
1% Triton X-100 in the lysis buffer, as indicated in the
text. SDS PAGE gels were stained with Coomassie brilliant
blue as standard.
Analysis of the oligomeric nature of VP2
Sf21 cell monolayers were infected with recombinant bac-
uloviruses (pAcNPV.VP2 or pAcNPV.VP2M1) at a MOI of
3. Cells were harvested at 72 hours post infection, washed
with PBS and lysed in 20 mM sodium phosphate buffer
containing 150 mM NaCl [pH 7.5], 1% [v/v] Triton X and
protease inhibitors (Sigma-Aldrich) at 4°C for 10 min-
utes. The lysate was clarified by centrifugation for 10 min
at 10,000 rpm (Sanyo Micro Centaur, Jepson Bolton & Co
Ltd, Watford, United Kingdom) and sample buffer added
to a final concentration of (1% SDS, 15% glycerol, 10 mM
Tris-HCl [pH 6.8], 0.02% [wt/vol] bromophenol blue)
without 1% β-mercaptoethanol, without heating, and
resolved by SDS-7% PAGE followed by western blotting.
Western blot analysis
SDS-PAGE separated proteins were transferred onto a
Hybond enhanced chemiluminescence nitrocellulose
membrane (GE Healthcare, Uppsala Sweden) as
described previously [44] and were probed with appropri-
ate antibodies to GFP, vimentin, tubulin, lamin and actin.
Subsequently, the blots were incubated with alkaline
phosphatase conjugated secondary antibodies and devel-
oped with BCIP-NBT substrate (Sigma-Aldrich).
Treatment of the cells with cytoskeleton inhibitors
Cells were washed 48 hours post transfection and incu-
bated in medium with 50 μM of acrylamide (24 hours) or
5 μg/ml of colchicine (2 hours). They were then processed
for immunofluorescence staining as described above. To
examine the effect of the inhibitors on viral yield at differ-
ent time points, the cells were first infected as described
previously and then pharmacologically treated. Cell
supernatant and cell pellets were collected and were sub-
jected to three freeze/thaw cycles to disrupt cells and to
release virus. All samples were collected, the viral titer of
each sample was determined in triplicate by virus plaque
assay in BSR cell monolayer cultures. Infectivity titers were
calculated as log10 pfu/ml, and the mean and standard
error of the reduction mediated by each inhibitor was cal-
culated (Sigma-AldrichPlot 2000, SYSTAT Software Inc.).
All the pharmacological treatments were performed in
duplicate and the plaque assay in triplicate.
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